Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07009717 · ClinicalTrials.gov registry record

Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

A clinical trial of Healthy and Chemotherapy Induced Peripheral Neuropathy (CIPN), sponsored by University of Florida.

Recruiting
Registry status
30
Enrollment target
1
Study location

NCT07009717: Recruiting study of Healthy and Chemotherapy Induced Peripheral Neuropathy (CIPN), sponsored by University of Florida.

NCT07009717 is a study of Healthy and Chemotherapy Induced Peripheral Neuropathy (CIPN) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07009717, a study of Healthy and Chemotherapy Induced Peripheral Neuropathy (CIPN), is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
30 participants
Enrollment target
1
Study location

Study Summary

Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to evaluate GTS in individuals with CIPN and healthy adults using ToeScale and see how it relates to nerve issues from chemotherapy. Additionally, we aim to assess the usability of the novel GTS assessment device, ToeScale among the participants. As a part of this study visit, you will complete some questionnaires followed by GTS and balance and gait assessments.

Primary Outcome

Measured using the ToeScale, the novel device used in this study to evaluate both flexion and extension strength of the great toe

Conditions Studied

Healthy Chemotherapy Induced Peripheral Neuropathy (CIPN)

Interventions

  • OTHER No intervention (observational study)

Study Locations (1)

Florida

  • University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-08-05
Est. Completion 2026-12-31
University of Florida

1,106 total trials

What NCT07009717 shows while recruiting

NCT07009717 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which No intervention (observational study) is the first listed.

NCT07009717 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT07009717 about?

NCT07009717 is a clinical study titled "Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)". Great Toe Strength (GTS) is a potential clinical biomarker that has been associated with functional mobility and health; Additionally, GTS has been identified in the literature as one of the early symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this research study is to...

What is the current status of trial NCT07009717?

This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-08-05. Estimated completion is 2026-12-31.

What conditions does trial NCT07009717 study?

This clinical trial studies the following conditions: Healthy, Chemotherapy Induced Peripheral Neuropathy (CIPN).

What interventions are being tested in trial NCT07009717?

The interventions under investigation include: No intervention (observational study) (OTHER).

Who is sponsoring clinical trial NCT07009717?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07009717 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07009717's enrollment target sits among peer trials

30 678th of 1090 higher than 363 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07009717

Source: ClinicalTrials.gov NCT07009717, the US trial registry maintained by the National Library of Medicine. NCT07009717 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.